The Science and Practice of Medication-Assisted Treatments for Opioid Dependence

REFERENCES

• Abbott, P. J., Weller, S. B., Delaney, H. D., & Moore, B. A. (1998). Community reinforcement approach in the treatment of opiate addicts. American Journal of Drug and Alcohol Abuse, 24(1), 17–30.
   PubMed Web of Science ®Google Scholar
• Abouyanni, G., Stevens, L. J., Harris, M. F., Wickes, W. A., Ramakrishna, S. S., Ta, E., (2000). GP attitudes to managing drug- and alcohol-dependent patients: a reluctant role. Drug and Alcohol Review, 19(2), 165–170.
   Web of Science ®Google Scholar
• Acker, C. J. (1997). The early years of the PHS Narcotic Hospital at Lexington, Kentucky. Public Health Reports, 112, 245–247.
   PubMed Web of Science ®Google Scholar
• Amato, L., Davoli, M., Minozzi, S., Ali, R., & Ferri, M. (2005). Methadone at tapered doses for the management of opioid withdrawal. Cochrane Database of Systematic Reviews, 3, Art. No. CD003409; doi: 10.1002 /14651858.CD003409.pub3.
   Google Scholar
• Amato, L., Minozzi, S., Davoli, M., Vecchi, S., Ferri, M., & Mayet, S. (2008a). Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database of Systematic Reviews, 4, Art. No. CD005031; doi: 10.1002/14651858.CD005031.pub3.
   Google Scholar
• Amato, L., Minozzi, S., Davoli, M., Vecchi, S., Ferri, M. M., & Mayet, S. (2008b). Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database of Systematic Reviews, 4, Art. No. CD005031; doi:10.1002/14651858.CD005031.pub3.
   Google Scholar
• Andrews, S., Sorensen, J. L., Guydish, J., Delucchi, K., & Greenberg, B. (2006). Knowledge and attitudes about methadone maintenance among staff working in a therapeutic community. Journal of Maintenance in the Addictions, 3(1), 47–59.
   Google Scholar
• Angarola, R. T. (1990). National and international regulation of opioid drugs: purpose, structures, benefits and risks. Journal of Pain and Symptom Management, 5(1 suppl.), S6–S11.
   PubMedGoogle Scholar
• Aragón-Poce, F., Martinez-Fernandez, E., Marquez-Espinos, C., Perez, A., Mora, R., & Torres, L. M. (2002). History of opium. International Congress Series, 1242, 19–21.
   Google Scholar
• ASAM (American Society of Addiction Medicine). (2006). ASAM public policy statement on methadone treatment of addiction. Chevy Chase, MD: Author.
   Google Scholar
• Avants, S. K., Margolin, A., Usubiaga, M. H., & Doebrick, C. (2004). Targeting HIV-related outcomes with intravenous drug users maintained on methadone: a randomized clinical trial of a harm reduction group therapy. Journal of Substance Abuse Treatment, 26(2), 67–78.
   PubMed Web of Science ®Google Scholar
• Bacon, S. D. (2008). The classic Temperance Movement of the USA: impact today on attitudes, action and research. British Journal of Addiction to Alcohol & Other Drugs, 62(1–2), 5–18.
   Google Scholar
• Ball, J. C., & Ross, A. (1991). The effectiveness of methadone maintenance treatment. New York: Springer-Verlag.
   Google Scholar
• Baumohl, J., & White, W. (2003). Treatment institutions. In J. Blocker & I. Tyrell (Eds.), Alcohol and temperance in modern history (pp. 619–624). Santa Barbara, CA: ABC-CLIO.
   Google Scholar
• Bell, J., Chan, J., & Kuk, A. (1995). Investigating the influence of treatment philosophy on outcome of methadone maintenance. Addiction, 90(6), 823–830.
   PubMed Web of Science ®Google Scholar
• Bendtsen, P., & Akerlind, I. (1999). Changes in attitudes and practices in primary health care with regard to early intervention for problem drinkers. Alcohol and Alcoholism, 34(5), 795–800.
   PubMed Web of Science ®Google Scholar
• Berridge, V. (1982). Part I. Historical perspectives: opiate use in England, 1800–1926. Annals of the New York Academy of Sciences, 398, 1–11.
   PubMed Web of Science ®Google Scholar
• Bickel, W. K., Amass, L., Higgins, S. T., Badger, G. J., & Esch, R. A. (1997). Effects of adding behavioral treatment to opioid detoxification with buprenorphine. Journal of Consulting and Clinical Psychology, 65(5), 803–810.
   PubMed Web of Science ®Google Scholar
• Blumberg, H., & Dayton, H. B. (1973). Naloxone and related compounds. In H. W. Kosterlitz, J. O. Collier & J. Villarreal (Eds.), Agonist and antagonist actions of narcotic analgesic drugs (pp. 110–119). New York: Macmillan.
   Google Scholar
• Brown, B. S., Jansen, D. R., & Bass, U. F. (1974). Staff attitudes and conflict regarding the use of methadone in the treatment of heroin addiction. American Journal of Psychiatry, 131, 215–219.
   PubMed Web of Science ®Google Scholar
• Brownstein, M. J. (1993). A brief history of opiates, opioid peptides, and opioid receptors. Proceedings of the National Academy of Sciences, 90(12), 5391–5393.
   PubMed Web of Science ®Google Scholar
• Caplehorn, J. R. M., & Bell, J. (1991). Methadone dosage and retention of patients in maintenance treatment. Medical Journal of Australia, 154(3), 195–199.
   PubMed Web of Science ®Google Scholar
• Caplehorn, J. R. M., Bell, J., Klein, D. G., & Gebski, V. J. (1993). Retention in methadone maintenance and addicts’ risk of death. Addiction, 89(2), 203–207.
   Web of Science ®Google Scholar
• Caplehorn, J. R. M., Hartel, D. M., & Irwig, L. (1997). Measuring and comparing the attitudes and beliefs of staff working in New York methadone maintenance clinics. Substance Use & Misuse, 32(4), 399–413.
   PubMed Web of Science ®Google Scholar
• Caplehorn, J. R. M., lrwig, L., & Saunders, J. B. (1996). Physicians’ attitudes and retention of patients in their methadone maintenance programs. Substance Use & Misuse, 31(6), 663–667.
   PubMed Web of Science ®Google Scholar
• Caplehorn, J. R. M., Lumley, T. S., & lrwig, L. (1998). Staff attitudes and retention of patients in methadone maintenance programs. Drug and Alcohol Dependence, 52(1), 57–61.
   PubMed Web of Science ®Google Scholar
• Caplehorn, J. R. M., Lumley, T. S., Irwig, L., & Saunders, J. B. (1998). Changing attitudes and beliefs of staff working in methadone maintenance programs. Australian and New Zealand Journal of Public Health, 22(4), 505–508.
   PubMed Web of Science ®Google Scholar
• Carise, D. A., McLellan, A. T., & Gifford, L. S. (2000). Development of a “treatment program” descriptor: the addiction treatment inventory. Substance Use & Misuse, 35(12–14), 1797–1818.
   PubMed Web of Science ®Google Scholar
• Carise, D. A., McLellan, A. T., Gifford, L. S., & Kleber, H. D. (1999). Developing a national addiction treatment information system: an introduction to the drug evaluation network system. Journal of Substance Abuse Treatment, 17(1–2), 67–77.
   PubMed Web of Science ®Google Scholar
• Carreño, J. E., Alvarez, C. E., San Narciso, G. I., Bascaran, M. T., Díaz, M., & Bobes, J. (2003). Maintenance treatment with depot opioid antagonists in subcutaneous implants: an alternative in the treatment of opioid dependence. Addiction Biology, 8(4), 429–438.
   PubMed Web of Science ®Google Scholar
• Carrieri, M. P., Amass, L., Lucas, G. M., Vlahov, D., Wodak, A., & Woody, G. E. (2006). Buprenorphine use: the international experience. Clinical Infectious Diseases, 43(S4), S197–S215.
   Google Scholar
• Carroll, K. M., Ball S. A., Nich, C., O'Connor, P. G., Eagan, D. A., Frankforter, T. L., (2001). Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: efficacy of contingency management and significant other involvement. Archives of General Psychiatry, 58(8), 755–761.
   PubMed Web of Science ®Google Scholar
• Castells, X., Kosten, T. R., Capellà, D., Vidal, X., Colom, J., & Casas, M. (2009). Efficacy of opiate maintenance therapy and adjunctive interventions for opioid dependence with comorbid cocaine use disorders: a systematic review and meta-analysis of controlled clinical trials. American Journal of Drug and Alcohol Abuse, 35(5), 339–349.
   PubMed Web of Science ®Google Scholar
• Chander, G., Himelhoch, S., & Moore, R. D. (2006). Substance abuse and psychiatric disorders in HIV-positive patients: epidemiology and impact on antiretroviral therapy. Drugs, 66(6), 769–789.
   PubMed Web of Science ®Google Scholar
• Chappel, J. N., Veach, T. L., & Krug, R. S. (1985). The substance abuse attitude survey: an instrument for measuring attitudes. Journal of Studies on Alcohol, 46(1), 48–52.
   PubMed Web of Science ®Google Scholar
• Comer, S. D., Sullivan, M. A., Yu, E., Rothenberg, J. L., Kleber, H. D., Kampman, K., (2006). Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Archives of General Psychiatry, 63(2), 210–218.
   PubMed Web of Science ®Google Scholar
• CSAT Buprenorphine Information Center. (2010). Frequently asked questions about buprenorphine and the Drug Addiction Treatment Act of 2000 (DATA 2000). Retrieved from http://buprenorphine.samhsa.gov/faq.html#A11
   Google Scholar
• Dave, D., & Mukerjee, S. (2011). Mental health parity legislation, cost-sharing and substance abuse treatment admissions. Health Economics, 20(2), 161–183.
   Google Scholar
• Davenport-Hines, R. (2004). The pursuit of oblivion: A global history of narcotics. New York: W.W. Norton & Company.
   Google Scholar
• Dennis, M. L., & Scott, C. K. (2007). Managing addiction as a chronic condition. Addiction Science and Clinical Practice, 4(1), 45–55.
   PubMedGoogle Scholar
• DeQuincey, T. (1821). Confessions of an opium eater. London Magazine, September and October.
   Google Scholar
• Dole, V. P., & Nyswander, M. E. (1965). A medical treatment for diacetylmorphine (Heroin) addiction: a clinical trial with methadone hydrochloride. Journal of the American Medical Association, 193(8), 646–650.
   PubMed Web of Science ®Google Scholar
• Dole, V. P., & Nyswander, M. E. (1967) Heroin addiction: a metabolic disease. Archives of Internal Medicine, 120(1),19–24.
   PubMed Web of Science ®Google Scholar
• Dole, V. P., Nyswander, M. E., & Kreek, M. J. (1966). Narcotic blockade. Archives of Internal Medicine, 118(4), 304–309.
   PubMed Web of Science ®Google Scholar
• Durrant, R., & Thakker, J. (2003). Substance use and abuse: Cultural and historical perspectives. Thousand Oaks, CA: Sage.
   Google Scholar
• Dwarakanath, S. C. (1965). Use of opium and cannabis in the traditional systems of medicine in India. Bulletin on Narcotics, 17(1), 15–19.
   Google Scholar
• Eissenberg, T., Greenwald, M. K., Johnson, R. E., Liebson, I. A., Bigelow, G. E., & Stitzer, M. L. (1996). Buprenorphine's physical dependence potential: antagonist precipitated withdrawal in humans. Journal of Pharmacology and Experimental Therapeutics, 276(2), 449–459.
   PubMed Web of Science ®Google Scholar
• Eissenberg, T., Johnson, R. E., Bigelow, G. E., Walsh, S. L., Liebson, I. A., Strain, E. C., (1997). Controlled opioid withdrawal evaluation during 72 hour dose omission in buprenorphine-maintained patients. Drug and Alcohol Dependence, 45(1–2), 81–91.
   PubMed Web of Science ®Google Scholar
• Emmanuelli, J., & Desenclos, J. C. (2005). Harm reduction interventions, behaviours and associated health outcomes in France, 1996–2003. Addiction, 100(11), 1690–1700.
   PubMed Web of Science ®Google Scholar
• Faggiano, F., Vigna-Taglianti, F., Versino, E., & Lemma, P. (2003). Methadone maintenance at different dosages for opioid dependence. Cochrane Database of Systematic Reviews, 3, Art. No. CD002208. doi: 10.1002/14651858.CD002208.
   Google Scholar
• Federal Bureau of Narcotics. (1955). Narcotics clinics in the United States. Washington, DC: U.S. Government Printing Office.
   Google Scholar
• Forman, R. F., Bovasso, G., & Woody, G. (2001). Staff beliefs about addiction treatment. Journal of Substance Abuse Treatment, 21(1), 1–9.
   PubMed Web of Science ®Google Scholar
• Fort, J. (1965). Giver of delight or liberator of sin: drug use and “addiction” in Asia. Bulletin on Narcotics, 17(3), 1–11.
   Google Scholar
• Foster, J., Brewer, C., & Steele, T. (2003). Naltrexone implants can completely prevent early (1-month) relapse after opiate detoxification: a pilot study of two cohorts totalling 101 patients with a note on naltrexone blood levels. Addiction Biology, 8(2), 211–217.
   PubMed Web of Science ®Google Scholar
• Friedmann, P. D., Lemon, S. C., Stein, M. D., & D'Aunno, T. A. (2003). Accessibility of addiction treatment: results from a national survey of outpatient substance abuse treatment organizations. Health Services Research, 38(3), 887–903.
   PubMed Web of Science ®Google Scholar
• Galea, S., Worthington, N., Piper, T. M., Nandi, V. V., Curtis, M., & Rosenthal, D. M. (2006). Provision of naloxone to injection drug users as an overdose prevention strategy: early evidence from a pilot study in New York City. Addictive Behaviors, 31(5), 907–912.
   PubMed Web of Science ®Google Scholar
• Gerlach, R., & Caplehorn, J. R. M. (1999). Attitudes and beliefs of doctors prescribing methadone to addicts in the Westfalen-Lippe region of Germany. Drug and Alcohol Review, 18(2), 163–170.
   Web of Science ®Google Scholar
• Giannetti, V. J., Sieppert, J. D., & Holosko, M. J. (2002). Attitudes and knowledge concerning alcohol abuse: curriculum implications. Journal of Health and Social Policy, 15(1), 45–58.
   PubMedGoogle Scholar
• Gilmore, W. C. (1991). Drug trafficking by sea: the 1988 United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances. Marine Policy, 15(3), 183–186.
   Web of Science ®Google Scholar
• Gossop, M., Keaney, F., Sharma, P., & Jackson, M. (2005). The unique role of diamorphine in British medical practice: a survey of general medical practitioners and hospital doctors. European Addiction Research, 11(2), 76–82.
   PubMed Web of Science ®Google Scholar
• Government Services. (1935). Opening of the federal narcotic farm at Lexington, KY. Journal of the American Medical Association, 104(7), 574.
   Google Scholar
• GPO. (1970). Controlled Substances Act: 21 USC 812. Washington, DC: U.S. Government Printing Office.
   Google Scholar
• Green, T. C., Heimer, R., & Grau, G. E. (2008). Distinguishing signs of opioid overdose and indication for naloxone: an evaluation of six overdose training and naloxone distribution programs in the United States. Addiction, 103(6), 979–989.
   PubMed Web of Science ®Google Scholar
• Griffith, J. D., Rowan-Szal, G. A., Roark, R. R., & Simpson, D. D. (2000). Contingency management in outpatient methadone treatment: A meta-analysis.Drug and Alcohol Dependence, 58(1–2), 55–66.
   PubMed Web of Science ®Google Scholar
• Gueye, P. N., Megarbane, B., Borron, S. W., Adnet, F., Galliot-Guilley, M., Ricordel, I., (2002). Trends in opiate and opioid poisonings in addicts in north-east Paris and suburbs, 1995–99.Addiction, 97(10), 1295–1304.
   PubMed Web of Science ®Google Scholar
• Hartel, D. (1990). Cocaine use, inadequate methadone dose increase risk of AIDS for IV drug users in treatment. NIDA Notes, 5(1), 16–17.
   Google Scholar
• Hartel, D., Schoenbaum, E. E., Selwyn, P. A., Friedland, G. H., Feingold, A. R., Alerman, M. H., (1989, June). Temporal patterns of cocaine use and AIDS in intravenous drug users in methadone maintenance. Proceedings of the 5th international conference on AIDS, Stockholm, Sweden.
   Google Scholar
• Hartel, D., Selwyn, P. A., Schoenbaum, E. E., Friedland, G. H., Feingold, A. R., Alerman, M. H., (1988, June). Methadone maintenance treatment and reduced risk of AIDS and AIDS-specific mortality in intravenous drug users. Proceedings of the 4th international conference on AIDS, Stockholm, Sweden.
   Google Scholar
• Haubrich, W. S. (2003). Medical meanings: A glossary of word origins (2nd ed.). Philadelphia, PA: American College of Physicians.
   Google Scholar
• Hawkins, J. (1937). Opium: Addicts and addictions. Danville, VA: J.T. Townes.
   Google Scholar
• Higgins S. T., Silverman, K., & Heil, S. H. (Eds.). (2008). Contingency management in substance abuse treatment. New York: Guilford Press.
   Google Scholar
• Hser, Y. I., Anglin, M. D., Grella, C., Longshore, D., & Prendergast, M. L. (1997). Drug treatment careers: a conceptual framework and existing research findings. Journal of Substance Abuse Treatment, 14(6), 543–558.
   PubMed Web of Science ®Google Scholar
• Hser, Y. I., Longshore, D., & Anglin, M. D. (2007). The life course perspective on continuing care for substance abuse treatment: a conceptual framework for understanding drug use trajectories. Evaluation Review: A Journal of Applied Social Research, 31(6), 515–547.
   PubMed Web of Science ®Google Scholar
• Hunt, D. (1992, March 19). Methadone clinic shut in raid here. Houston Chronicle, p. 1A.
   Google Scholar
• Hyashi, K., Wood, E., Wiebe, L., Qi, J., & Kerr, T. (2010). An external evaluation of a peer-run outreach-based syringe exchange in Vancouver, Canada. International Journal of Drug Policy, 21(5), 418–421.
   PubMed Web of Science ®Google Scholar
• Institute of Medicine (2006). Improving the Quality of Health Care for Mental and Substance-Use Disorders: Quality Chasm Series. Washington, DC: National Academy Press.
   Google Scholar
• Jaffe, J. H. (2000). Substance-related disorders: introduction and overview. In B. J. Sadock & M. D. Sadock (Eds.), Comprehensive textbook of psychiatry (7th ed., pp. 924–952). Philadelphia, PA: Lippincott Williams & Wilkins.
   Google Scholar
• JAMA. (1935). Narcotic farms: a public policy. Journal of the American Medical Association, 104(4), 566.
   Google Scholar
• Johnson, J. A., Knudsen, H., & Roman, P. (2002). Counselor turnover in private facilities. Frontlines: Linking Alcohol Services Research & Practice, November, pp. 5,8.
   Google Scholar
• Kahan, M., Wilson, L., Liu, E., Borsoi, D., Brewster, J. M., Sobell, L. C., (2004). Family medicine residents’ beliefs, attitudes and performance with problem drinkers: a survey and simulated patient study. Substance Abuse, 25(1), 43–51.
   PubMedGoogle Scholar
• Kerr, T., Small, W., Peeace, W., Douglas, D., Pierre, A., & Wood, E. (2006). Harm reduction by a “user-run” organization: a case study of the Vancouver Area Network of Drug Users (VANDU). International Journal of Drug Policy, 17(2), 61–69.
   Web of Science ®Google Scholar
• Kieffer, B. L., & Evans, C. J. (2002). Opioid tolerance: in search of the holy grail. Cell, 108(5), 587–590.
   PubMed Web of Science ®Google Scholar
• Kim, D., Irwin, K. S., & Khoshnood, K. (2009). Expanded access to naloxone: options for critical response to the epidemic of opioid overdose mortality. American Journal of Public Health, 99(3), 402–407.
   PubMed Web of Science ®Google Scholar
• Kleber, H. D. (2008). Methadone maintenance 4 decades later: thousands of lives saved but still controversial. Journal of the American Medical Association, 300(19), 2303–2305.
   PubMed Web of Science ®Google Scholar
• Knudson, H. K., Ducharme, L. J., & Roman, P. M. (2007). Research network involvement and addiction treatment center staff: counselor attitudes toward buprenorphine. American Journal on Addictions, 16(5), 365–371.
   PubMed Web of Science ®Google Scholar
• Krupitsky, E. M., & Blokhina, E. A. (2010). Long-acting depot formulations of naltrexone for heroin dependence: a review. Current Opinion in Psychiatry, 23(3), 210–214.
   PubMed Web of Science ®Google Scholar
• Krupitsky, E. M., Masalov, D. V., Didenko, T. Y., Burakov, A. M., Romanova, T. N., Zvartau, E. E., (2001). Prevention of suicide by naltrexone in a recently detoxified heroin addict. European Addiction Research, 7(2), 87–88.
   PubMed Web of Science ®Google Scholar
• Krupitsky, E. M., Nunes, E. V., Ling, W., Illeperuma, A., Gastfriend, D. R., & Silverman, B. L. (2011). Injectable extended-release naltresxone for opioid dependence: a double-blind, placebo-controlled, multicenter randomised trial. The Lancet, 377, 1506–1513.
   Google Scholar
• Krupitsky, E. M., Zvartau, E. E., Masalov, D. V., Tsoi, M. V., Burakov, A. M., Egorova, V. Y., (2004). Naltrexone for heroin dependence treatment in Russia. Journal of Substance Abuse Treatment, 26(4), 285–294.
   PubMed Web of Science ®Google Scholar
• Krupitsky, E. M., Zvartau, E. E., Masalov, D. V., Tsoi, M. V., Burakov, A. M., Egorova, V. Y., (2006). Naltrexone and fluoxetine for heroin dependence treatment in St. Petersburg, Russia. Journal of Substance Abuse Treatment, 31(4), 319–328.
   PubMed Web of Science ®Google Scholar
• Lenton, S. R., Dietze, P. M., Degenhardt, L., Darke, S., & Butler, T. G. (2009). Now is the time to take steps to allow peer access to naloxone for heroin overdose in Australia. Drug and Alcohol Review, 28(6), 583–585.
   PubMed Web of Science ®Google Scholar
• Lewis, J. (1998). In pursuit of the holy grail. Retrieved from http://www.cpdd.vcu.edu/Media/Index/AwardSpeeches/Lewis J._Eddy1998.pdf
   Google Scholar
• Lintzeris, N. (2009). Prescription of heroin for the management of heroin dependence: current status. CNS Drugs, 23(6),463–476.
   PubMed Web of Science ®Google Scholar
• Lobmaier, P., Kornør, H., Kunøe, N., & Bjørndal, A. (2008). Sustained-release naltrexone for opioid dependence. Cochrane Database of Systematic Reviews, 2, Art. No. CD006140. doi: 10.1002/14651858.CD006140.pub2.
   Google Scholar
• Loftis, J. M., Matthews, A. M., & Hauser, P. (2006). Psychiatric and substance use disorders in individuals with hepatitis C: epidemiology and management. Drugs, 66(2), 155–174.
   PubMed Web of Science ®Google Scholar
• Lowry, J. (1956). The hospital treatment of the narcotic addict. Federal Probation, 15, 42–51.
   Google Scholar
• Marlatt, G. A. (1998). Highlights of harm reduction. In G. A. Marlatt (Ed.), Harm reduction: Pragmatic strategies for managing high-risk behaviors (pp. 3–29). New York: Guilford Press.
   Google Scholar
• Marsh, J. C., Oviedo-Joekes, E., Perea-Milla, E., Carrasco, F., & PEPSA Team. (2006). Controlled trial of prescribed heroin in the treatment of opioid addiction. Journal of Substance Abuse Treatment, 31(2), 203–211.
   PubMed Web of Science ®Google Scholar
• Marshall, E. (1911, March 12). Uncle Sam is the worst drug fiend in the world. New York Times, p. SM12.
   Google Scholar
• Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2009). Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database of Systematic Reviews, 3, Art. No. CD002209. doi: 10.1002/14651858.CD002209.pub2.
   PubMed Web of Science ®Google Scholar
• Mattick, R. P., Kimber, J., Breen, C., & Davoli, M. (2008). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews, 2, Art. No. CD002207. doi: 10.1002/14651858.CD002207.pub3.
   Google Scholar
• Mayet, S., Farrell, M., Ferri, M., Amato, L., & Davoli, M. (2005). Psychosocial treatment for opiate abuse and dependence. Cochrane Database of Systematic Reviews, 1, Art. No. CD004330. doi: 10.1002/14651858.CD004330.pub2.
   Google Scholar
• McIntosh, C., & Ritson, B. (2001). Treating depression complicated by substance misuse. Advances in Psychiatric Treatment, 7(5), 357–364.
   Google Scholar
• McKeganey, N. (2008). Should heroin be prescribed to misusers? No. British Medical Journal, 336(7635), 71.
   PubMedGoogle Scholar
• McLellan, A. T., Carise, D., & Kleber, H. D. (2003). Can the national addiction treatment infrastructure support the public's demand for quality care? Journal of Substance Abuse Treatment, 25, 117–121.
   PubMed Web of Science ®Google Scholar
• McLellan, A. T., Lewis, D. C., O'Brien, C. P., & Kleber, H. D. (2000). Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. Journal of the American Medical Association, 284(13), 1689–1695.
   PubMed Web of Science ®Google Scholar
• McLellan, A. T., & Meyers, K. (2004). Contemporary addiction treatment: a review of systems problems for adults and adolescents. Biological Psychiatry, 56(10), 764–770.
   PubMed Web of Science ®Google Scholar
• McNulty, T. L., Oser, C. B., Johnson, J. A., Knudsen, H. K., & Roman, P. M. (2007). Counselor turnover in substance abuse treatment centers: an organizational-level analysis. Sociological Inquiry, 77(2), 166–193.
   Web of Science ®Google Scholar
• Metrebian, N., Carnwath, T., Stimson, G., & Storz, T. (2002). Survey of doctors prescribing diamorphine (heroin) to opiate-dependent drug users in the United Kingdom. Addiction, 97(9), 1155–1161.
   PubMed Web of Science ®Google Scholar
• Metzger, D. S., Woody, G. E., McLellan, A. T., O'Brien, C. P., Druley, P., Navaline, H., (1993). Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. Journal of Acquired Immune Deficiency Syndromes, 6(9), 1049–1056.
   Web of Science ®Google Scholar
• Meyers, R. J., Miller, W. R., Hill, D. E., & Toniga, J. S. (1998). Community reinforcement and family training (CRAFT): engaging unmotivated drug users in treatment. Journal of Substance Abuse, 10(3), 291–308.
   PubMedGoogle Scholar
• Meyers, R. J., & Smith, J. E. (1995). Clinical guide to alcohol treatment: The community reinforcement approach. New York: Guilford Press.
   Google Scholar
• Musto, D. F. (1987a). The history of legislative control over opium, cocaine, and their derivatives. In R. Homowy (Ed.), Dealing with drugs: Consequences of government control (pp. 37–50). San Francisco, CA: Pacific Research Institute for Public Policy.
   Google Scholar
• Musto, D. F. (1987b). The American disease: Origins of narcotic control (3rd ed.). New York: Oxford University Press.
   Google Scholar
• Musto, D. F. (1991). Opium, cocaine, and marijuana in American history. Scientific American, 265(1), 40–47.
   PubMed Web of Science ®Google Scholar
• Nahra, T. A., Alexander, J., & Pollack, H. (2009). Influence of ownership on access in outpatient substance abuse treatment. Journal of Substance Abuse Treatment, 36, 355–365.
   PubMed Web of Science ®Google Scholar
• Narcotics Anonymous World Services. (2009). NA World Services, Inc., annual report: 1 July 2008–30 June 2009. Van Nuys, CA: Author.
   Google Scholar
• NIDA. (2009). Principles of drug addiction treatment: A research based guide (2nd ed.). Bethesda, MD: National Institute on Drug Abuse.
   Google Scholar
• NIDA. (2010). NIDA/SAMHSA blending initiative. Retrieved from http://www.nida.nih.gov/Blending/index.html
   Google Scholar
• Needle, R. H., & Zhao, L. (2010). HIV prevention among injection drug users: A report of the CSIS Global Health Policy Center. Washington, DC: CSIS.
   Google Scholar
• Oviedo-Joekes, E., Brissette, S., Marsh, D. C., Lauzon, P., Guh, D., Anis, A., (2009). Diacetylmorphine versus methadone for the treatment of opioid addiction. New England Journal of Medicine, 361, 777–786.
   PubMed Web of Science ®Google Scholar
• Payte, J. T., & Khuri, E. T. (1993). Principles of methadone dose determination. In M. W. Parrino (Ed.), State methadone treatment guidelines (pp. 47–58). Bethesda, MD: Center for Substance Abuse Treatment.
   Google Scholar
• Prendergast, M., Podus, D., Finney, J., Greenwell, L., & Roll, J. (2006). Contingency management for treatment of substance use disorders: a meta-analysis. Addiction, 101(11), 1546–1560.
   PubMed Web of Science ®Google Scholar
• Preston, K. L., Silverman, K., Umbricht, A., DeJesus, A., Montoya, I. D., & Schuster, C. R. (1999). Improvement in naltrexone treatment compliance with contingency management. Drug and Alcohol Dependence, 54, 127–135.
   PubMed Web of Science ®Google Scholar
• Preston, K. L., Umbricht, A., & Epstein, D. H. (2000). Methadone dose increase and abstinence reinforcement for treatment of continued heroin use during methadone maintenance. Archives of General Psychiatry, 57(4), 395–404.
   PubMed Web of Science ®Google Scholar
• Regier, D. A., Farmer, M. E., Rae, D. S., Locke, B. Z., Keith, S. J., Judd, L. L., (1990). Comorbidity of mental disorders with alcohol and other drug abuse. Journal of the American Medical Association, 264(19), 2511–2518.
   PubMed Web of Science ®Google Scholar
• Rehm, J., & Fischer, B. (2008). Should heroin be prescribed to misusers? Yes. British Medical Journal, 336(7635), 70.
   PubMedGoogle Scholar
• Resnick, R. B. (1998). A practitioner's experience with naltrexone. Proceedings of the 29th annual scientific conference of the American Society of Addiction Medicine, New Orleans, LA.
   Google Scholar
• Rettig, R. A., & Yarmolinsky, A. (Eds.). (1995). Federal regulation of methadone treatment. Washington DC: National Academy Press.
   Google Scholar
• Rexed, B., Edmondson, D., Khan, I., & Samsom, R. J. (1984). Guidelines for the control of narcotic and psychotropic substances in the context of the international treaties. Geneva: World Health Organization.
   Google Scholar
• Robinson v. California, 370 US 660 (Supreme Court, 1962).
   Google Scholar
• Rush, B. R., Powell, L. Y., Crowe, T. G., & Ellis, K. (1995). Early intervention for alcohol use: family physicians’ motivations and perceived barriers. Canadian Medical Association Journal, 152(6), 863–869.
   Web of Science ®Google Scholar
• Salamina, G., Diecidue, R., Vigna-Taglianti, F., Jarre, P., Schifano, P., Bargagli, A. M., (2010). Effectiveness of therapies for heroin addiction in retaining patients in treatment: results from the Vedette study. Substance Use & Misuse, 45(12), 2076–2092.
   PubMed Web of Science ®Google Scholar
• Sertürner, F. W. A. (1806). Darstellung der reinen Mohnsäure (Opiumsäure), nebst einer chemischen Untersuchung des Opiums [Description of pure poppy acid: Opium acid and an analysis of opium]. Journal of Pharmacology, 14, 47–93.
   Google Scholar
• Sevarino, K. A., & Kosten, T. R. (2009). Naltrexone for initiation and maintenance of opiate abstinence. In R. Dean, E. J. Bilsky & S. S. Negus (Eds.), Opiate receptors and antagonists: From bench to clinic (pp. 227–245). New York: Humana.
   Google Scholar
• Shapiro, R. S. (1994). Legal bases for the control of analgesic drugs. Journal of Pain and Symptom Management, 9(3), 153–159.
   PubMed Web of Science ®Google Scholar
• Silverman, K., Wong, C. J., Higgins, S. T., Brooner, R. K., Montoya, I. D., Contoreggi, C., (1996). Increasing opiate abstinence through voucher-based reinforcement therapy. Drug and Alcohol Dependence, 41, 157–165.
   PubMed Web of Science ®Google Scholar
• Sloan, F. (2005). Not for profit ownership and hospital behavior. In A. J. Cuyler & J. P. Newhouse (Eds.), Handbook of health economics ( Vol. 1, pp. 1141–1174). Amsterdam: Elsevier Science BV.
   Google Scholar
• Smith, J. E., Meyers, R. J., & Miller, W. R. (2010). The community reinforcement approach to the treatment of substance use disorders. American Journal on Addictions, 10(s1), s51–s59.
   Google Scholar
• Smith, P. (2009a, February 13). Europe: Danish heroin maintenance program to commence next month. Drug War Chronicle, 572. Retrieved from http://stopthedrugwar.org/ chronicle/2009/feb/13/europe_danish_heroin_maintenance
   Google Scholar
• Smith, P. (2009b, June 5). Europe: German parliament approves heroin maintenance. Drug War Chronicle, 588. Retrieved from http://stopthedrugwar.org/chronicle/2009/jun/05/europe_german _parliament_approve
   Google Scholar
• Solomon, L. M. (2002). The resilient sector: the state of nonprofit America. In L. M. Solomon (Ed.), The state of nonprofit America (pp. 3–61). Washington, DC: Brookings Institution Press.
   Google Scholar
• Stimson, G. V., & Metrebian, N. (2003). Prescribing heroin: What is the evidence? London: Rowntree Foundation.
   Google Scholar
• Strang, J., & Gossop, M. (2005). Heroin addiction and the British system. New York: Routledge.
   Google Scholar
• Strang, J., Manning, V., Mayet, S., Best, D., Titherington, E., Santana, L., (2008). Overdose training and take-home naloxone for opiate users: prospective cohort study of impact on knowledge and attitudes and subsequent management of overdoses. Addiction, 103(10), 1648–1657.
   PubMed Web of Science ®Google Scholar
• Subramaniam, G. A., Fishman, M. J., & Woody, G. (2009). Treatment of opioid-dependent adolescents and young adults with buprenorphine. Current Psychiatry Reports, 11(5), 360–363.
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. (2008). National survey of substance abuse treatment services (N-SSATS): 2007. Data on substance abuse treatment facilities. Rockville, MD: SAMHSA/Office of Applied Studies.
   Google Scholar
• Substance Abuse and Mental Health Services Administration. (2010). The national survey of substance abuse treatment services (N-SSATS) report: Free substance abuse treatment. Rockville, MD: SAMHSA/Office of Applied Studies.
   Google Scholar
• Sullivan, M. A., Vosburg, S. K., & Comer, S. D. (2006). Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin. Psychopharmacology, 189(1), 37–46.
   PubMed Web of Science ®Google Scholar
• Terry, C. E., & Pellens, M. (1928). The opium problem. New York: Bureau of Social Hygiene.
   Google Scholar
• Teruya, C., Thomas, C., Rosensteel, A., Hasson, A., Hillhouse, M., Hser, Y., (2010, June). START study retention: perspectives of suboxone dropouts. Poster presented at the College on Problems of Drug Dependence (CPDD) annual meeting, Scottsdale, AZ.
   Google Scholar
• UNAIDS (The Joint United Nations Programme on HIV/AIDS). (2006). Report on the global AIDS epidemic. Geneva: UNAIDS. Retrieved from http://www.unaids.org/en/Knowledge Centre/HIVData/GlobalReport/2006/
   Google Scholar
• United Nations. (1961). Single convention on narcotic drugs, 1961. Retrieved from http: //www.unodc.org/pdf/ convention_1961_en.pdf
   Google Scholar
• United Nations. (1971). Convention on psychotropic substances, 1971. Retrieved from http: //www.incb.org/pdf/e/conv/ convention_1971_en.pdf
   Google Scholar
• United Nations. (1988). United Nations convention against illicit traffic in narcotic drugs and psychotropic substances. Retrieved from http: //www.unodc.org/pdf/convention_1988_en.pdf
   Google Scholar
• United Nations International Drug Control Program. (2000). Bulletin on narcotics. New York: United Nations.
   Google Scholar
• UNODC (United Nations Office on Drug Control Policy). (2007). 2007 World drug report. Geneva: UNODC.
   Google Scholar
• UNODC. (2010). Treatnet. Retrieved from http://www.unodc.org/ treatment/index.html
   Google Scholar
• U.S. Census Bureau. (2004). The AIDS pandemic in the 21st century: International population reports. Washington, DC: U.S. Government Printing Office.
   Google Scholar
• van den Brink, W., Hendriks, V. M., Blanken, P., Koeter, M. W. J., van Zwieten, B. J., & van Ree, J. M. (2003). Medical prescription of heroin to treatment resistant heroin addicts: two randomized controlled trials. BMJ, 327(7410), 310.
   PubMed Web of Science ®Google Scholar
• Verthein, U., Bonorden-Kleij, K., Degkwitz, P., Dilg, C., Köhler, W. K., Passie, T., (2008). Long-term effects of heroin-assisted treatment in Germany. Addiction, 103(6), 960–966.
   PubMed Web of Science ®Google Scholar
• Volkow, N. D., & Li, T. K. (2004). Drug addiction: the neurobiology of behaviour gone awry. Nature Reviews Neuroscience, 5(12), 963–970.
   PubMed Web of Science ®Google Scholar
• Walsh, S. L., Preston, K. L., Stitzer, M. L., Cone, E. J., & Bigelow, G. E. (1994). Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clinical Pharmacology & Therapeutics, 55(5), 569–580.
   PubMed Web of Science ®Google Scholar
• White, W. L. (1998). Slaying the dragon: The history of addiction treatment and recovery in America. Normal, IL: Chestnut Health Systems.
   Google Scholar
• White, W. L. (2002). Trick or treat? A century of American responses to heroin addiction. In D. Musto (Ed.), One hundred years of heroin. Westport, CT: Auburn House.
   Google Scholar
• WHO (World Health Organization). (2003). WHO expert committee on drug dependence. WHO Technical Report Series. Geneva: Author.
   Google Scholar
• WHO. (2004). Neuroscience of psychoactive substance use and dependence. Geneva: Author.
   Google Scholar
• WHO. (2005a). Indonesia (Summary country profile for HIV/AIDS treatment scale-up). Retrieved from http://www. who.int/hiv/HIVCP_IDN.pdf
   Google Scholar
• WHO. (2005b). World Health Organization overview of Malaysia: Injecting drug use and HIV/AIDS. Kunming: Author.
   Google Scholar
• WHO. (2008). The methadone fix. Bulletin of the World Health Organization, 86(3), 164–165.
   PubMed Web of Science ®Google Scholar
• WHO. (2009a). Country office for Viet Nam: 2009 year in review. Retrieved from http://www.wpro.who.int/NR/rdonlyres/DC0 0105B-9993-4A9C-8BA4-B587697C043A/0/Year_In_Review_ 2009_FINAL.pdf
   Google Scholar
• Williams, J. T., Christie, M. J., & Manzoni, O. (2001). Cellular and synaptic adaptations mediating opioid dependence. Physiological Reviews, 81(1), 299–343.
   PubMed Web of Science ®Google Scholar
• Woody, G. E., Poole, S. A., Subramaniam, G., Dugosh, K., Bogenschutz, M., Abbott, P., (2008). Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. Journal of the American Medical Association, 300(17), 2003–2011.
   PubMed Web of Science ®Google Scholar
• Wright, C. R. A. (1874). On the action of organic acids and their anhydrides on the natural alkaloids. Journal of the Chemical Society, 27, 1031–1043.
   Google Scholar
• Wu, E., El-Bassel, N., Gilbert, L., Chang, M., & Sanders, G. (2010). Effects of receiving additional off-site services on abstinence from illicit drug use among men on methadone: a longitudinal study. Evaluation and Program Planning, 33(4), 403–409.
   PubMed Web of Science ®Google Scholar
• Zanis, D. A., & Woody G. E. (1998). One year mortality rates following methadone treatment discharge. Drug and Alcohol Dependence, 52(3), 257–260.
   PubMed Web of Science ®Google Scholar